Sinovac Biotech (SVA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$402.8M

Revenue (quarter)

$147.1M

Revenue growth (year over year)

+12.90%

Gross profit (trailing twelve months)

$276.1M

Gross margin

68.53%

Net income (trailing twelve months)

−$193.7M

Net income (quarter)

−$91.4M

Net income growth (year over year)

+5.34%

Net margin

−48.08%

Return on equity

−2.21%

EPS (trailing twelve months)

−$1.37

Book value per share

$75.01

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

20.57%

Payout ratio

−5535.08%

Dividend yield

—

Company profile

Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.

• Is Sinovac Biotech (SVA) profitable?

  No. Sinovac Biotech reported a net loss of $193.7M over the trailing twelve months.

• How much revenue does Sinovac Biotech (SVA) make?

  Sinovac Biotech generated $402.8M in revenue over the trailing twelve months, up 12.90% year over year.

• How do I buy stock in Sinovac Biotech (SVA)?

  SVA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.